本發明是有關於一種用藥處方建議方法及系統，特別關於一種方便於醫療人員使用並可減少用藥浪費之智慧化用藥處方建議方法及系統。The present invention relates to a medication prescription recommendation method and system, and more particularly to an intelligent medication prescription recommendation method and system that is convenient for medical personnel to use and can reduce medication waste.
近年來，隨著高齡化社會的來臨，慢性疾病佔健康保險中的支出比例也跟著逐年增加。特別的是當人們隨著身體的老化，經常會伴隨著多重疾病的發生，而此多重疾病是指有兩項以上的慢性病，如此導致慢性病的相關醫療及用藥成本大幅增加。In recent years, with the advent of an aging society, the proportion of chronic diseases in health insurance expenditures has also increased year by year. In particular, as people age, they are often accompanied by the occurrence of multiple diseases, and multiple diseases refer to having more than two chronic diseases, which leads to a significant increase in the medical and drug costs related to chronic diseases.
根據國民健康署的調查中發現，65歲以上的民眾中的8成有至少一種慢性病，7成以上有兩種以上的慢性病，5成以上有著三種以上的慢性病，其中常見的慢性病包含了高血壓、高血糖、高血脂、白內障、心臟病、糖尿病、關節炎、腎臟病、骨質疏鬆症等。當年齡逐漸增加的時候，身體的功能會不斷退化，疾病也會逐一的發生，如果再加上不良的生活習慣，像是久坐缺少運動、抽菸、喝酒、吃檳榔、高糖高鹽高肪飲食等等，有慢性疾病的比例就會更高，而通常一個慢性疾病也容易會引發另一個慢性疾病的發生。According to a survey conducted by the National Health Administration, 80% of people over 65 have at least one chronic disease, more than 70% have two or more chronic diseases, and more than 50% have three or more chronic diseases. Common chronic diseases include high blood pressure, high blood sugar, high blood lipids, cataracts, heart disease, diabetes, arthritis, kidney disease, osteoporosis, etc. As people age, their body functions will continue to deteriorate and diseases will occur one by one. If they also have bad lifestyle habits, such as long-term sitting and lack of exercise, smoking, drinking, eating betel nuts, and high-sugar, high-salt, and high-fat diets, the proportion of people with chronic diseases will be even higher, and usually one chronic disease can easily lead to the occurrence of another chronic disease.
因此，如何有效降低「慢性疾病」相關醫療及用藥的成本，儼然成為政府以及世界各國在施政時所必須要面對的現實問題。Therefore, how to effectively reduce the cost of medical treatment and medication related to "chronic diseases" has become a realistic problem that governments and countries around the world must face when implementing policies.
為解決上述之問題，本發明之一目的係在於提供一種智慧化用藥處方建議方法，包含：一藥歷資料取得步驟，獲取一病患的藥歷資料，該藥歷資料的資料來源包含一雲端藥歷及一本院藥歷，該藥歷資料中包含有複數個藥品名稱及使用該些藥品名稱之該雲端藥歷及該本院藥歷；一藥品名稱排序步驟，智慧排序該些藥品名稱，以將該些藥品名稱按照英文字母順序進行排序，匯入並顯示於一第一藥歷清單列表；一資料來源提示步驟，利用顏色標示該藥歷資料的資料來源，以將該藥歷資料的資料來源中的該雲端藥歷及該本院藥歷分別以不同顏色顯示於該第一藥歷清單列表；一藥品名稱權重偵測步驟，利用一權重評估指標偵測該第一藥歷清單列表之該些藥品名稱，以對該些藥品名稱進行權重評估；一藥品名稱依權重排序加入步驟，將該第一藥歷清單列表中的該些藥品名稱依照權重大小進行排序並篩選加入到一第二藥歷清單列表；一相同成分重複用藥提示步驟，利用一相同成分重複指標偵測該第二藥歷清單列表之該些藥品名稱的成分名稱，以挑選出不同醫院使用相同成分的該些藥品名稱，並用顏色提示有重複的相同成分，以供評估是否續用；及一藥品名稱點選續用或刪除步驟，點選該第二藥歷清單列表之該些藥品名稱中之至少一該藥品名稱並予以續用或刪除。In order to solve the above-mentioned problems, one of the purposes of the present invention is to provide a smart medication prescription recommendation method, comprising: a medication history data acquisition step, obtaining a patient's medication history data, the data source of the medication history data comprising a cloud medication history and a hospital medication history, the medication history data comprising a plurality of drug names and the cloud medication history and the hospital medication history using the drug names; a drug name sorting step, intelligently sorting the drug names, so as to sort the drug names in alphabetical order, importing and displaying them in a first medication history list; a data source prompting step, using color to mark the data source of the medication history data, so as to display the cloud medication history and the hospital medication history in the data source of the medication history data in different colors in the first medication history list; a drug name A weight detection step, using a weight evaluation index to detect the drug names in the first drug history list to evaluate the weight of the drug names; a drug name addition step according to weight sorting, sorting the drug names in the first drug history list according to the weight size and screening and adding them to a second drug history list; a same ingredient duplicate medication prompt step, using a same The component duplication indicator detects the component names of the drug names in the second medication history list to select the drug names with the same components used in different hospitals, and uses color to indicate the duplicated identical components for evaluation of whether to continue using; and a drug name click to continue or delete step, click at least one of the drug names in the second medication history list to continue or delete it.
如上述之智慧化用藥處方建議方法，更包含：一減少藥物交互作用提示步驟，利用一藥物交互作用指標偵測該第二藥歷清單列表之該些藥品名稱的成分名稱，以挑選出不同醫院所使用不同成分的該些藥品名稱彼此之間會產生藥物交互作用，並用顏色提示有藥物交互作用的不同成分，以供評估是否續用。The intelligent medication prescription recommendation method as mentioned above further includes: a step of reducing drug interaction prompts, using a drug interaction indicator to detect the ingredient names of the drug names in the second medication history list, so as to select the drug names with different ingredients used in different hospitals that will produce drug interactions with each other, and use colors to prompt different ingredients with drug interactions for evaluation of whether to continue using them.
如上述之智慧化用藥處方建議方法，其中，該權重評估指標的考量參數係選自慢性藥品、本院醫療體系藥品、非本院醫療體系藥品、雲端藥歷天數大於7天、病人年齡、藥物劑型、藥物給藥頻次、藥物副作用或過敏史、重複用藥、藥物交互作用、病人生活習慣-抽菸、病人生活習慣-喝酒、病人肝功能、病人腎功能、病人共病、懷孕和藥物、基因與藥物之一或其組合。As in the above-mentioned intelligent medication prescription recommendation method, the consideration parameters of the weight evaluation index are selected from chronic drugs, drugs in the hospital's medical system, drugs outside the hospital's medical system, cloud medication history greater than 7 days, patient age, drug dosage form, drug administration frequency, drug side effects or allergy history, repeated medication, drug interactions, patient lifestyle-smoking, patient lifestyle-drinking, patient liver function, patient kidney function, patient comorbidity, pregnancy and drugs, genes and drugs, or one or a combination thereof.
如上述之智慧化用藥處方建議方法，其中，該藥品名稱權重偵測步驟更包含：一權重評估指標建立步驟，建立該權重評估指標，其中該權重評估指標建立步驟包含：一權重評估指標參數設定步驟，設定該權重評估指標所需要的複數個考量參數；以及一權重評估指標評分設定步驟，設定該些考量參數所對應的複數個評分。As mentioned above, the intelligent medication prescription recommendation method, wherein the drug name weight detection step further includes: a weight evaluation index establishment step, establishing the weight evaluation index, wherein the weight evaluation index establishment step includes: a weight evaluation index parameter setting step, setting a plurality of consideration parameters required for the weight evaluation index; and a weight evaluation index score setting step, setting a plurality of scores corresponding to the consideration parameters.
如上述之智慧化用藥處方建議方法，其中，該智慧化用藥處方建議方法更包含：一藥品名稱點選加入步驟，點選該第一藥歷清單列表之該些藥品名稱中之至少一該藥品名稱，以加入到該第二藥歷清單列表。As described above, the intelligent medication prescription recommendation method further comprises: a drug name selection and adding step, clicking at least one of the drug names in the first medication history list to add it to the second medication history list.
本發明的另一目的在於提供一種智慧化用藥處方建議系統，包含：一資料接收模組，用以獲取一病患的藥歷資料，該藥歷資料的資料來源包含一雲端藥歷及一本院藥歷，該藥歷資料中包含有複數個藥品名稱及使用該些藥品名稱之該雲端藥歷及該本院藥歷；一資料顯示模組，訊號連接該資料接收模組，用以顯示出該病患的藥歷資料；一智慧排序模組，訊號連接該資料顯示模組，用以智慧排序該病患的藥歷資料中所出現的該些藥品名稱，以將該些藥品名稱按照英文字母順序進行排序，匯入並顯示於一第一藥歷清單列表；一資料來源提示模組，訊號連接該資料顯示模組，用以利用顏色標示該藥歷資料的資料來源，以將該藥歷資料的資料來源中的該雲端藥歷及該本院藥歷分別以不同顏色顯示於該第一藥歷清單列表；一藥品名稱權重偵測加入模組，訊號連接該資料顯示模組，用以利用一權重評估指標偵測該第一藥歷清單列表之該些藥品名稱，以對該些藥品名稱進行權重評估，且將該第一藥歷清單列表中的該些藥品名稱依照權重大小進行排序並篩選加入到一第二藥歷清單列表；一相同成分重複用藥提示模組，訊號連接該資料顯示模組，用以利用一相同成分重複指標偵測該第二藥歷清單列表之該些藥品名稱的成分名稱，以挑選出不同醫院使用相同成分的該些藥品名稱，並用顏色提示有重複的相同成分，以供評估是否續用；及一藥品名稱點選續用或刪除模組，訊號連接該資料顯示模組，用以點選該第二藥歷清單列表之該些藥品名稱中之至少一該藥品名稱並予以續用或刪除。Another object of the present invention is to provide an intelligent medication prescription recommendation system, comprising: a data receiving module for obtaining a patient's medication history data, the data source of the medication history data comprising a cloud medication history and a local hospital medication history, the medication history data comprising a plurality of drug names and the cloud medication history and the local hospital medication history using the drug names; a data display module, signal-connected to the data receiving module, for displaying the patient's medication history data; an intelligent sorting module; module, which is connected to the data display module by signal, and is used to intelligently sort the names of the drugs appearing in the patient's drug history data, so as to sort the drug names in alphabetical order, import and display them in a first drug history list; a data source prompt module, which is connected to the data display module by signal, and is used to use color to mark the data source of the drug history data, so as to display the cloud drug history and the hospital drug history in the data source of the drug history data in different colors respectively. The first medication history list is displayed; a drug name weight detection and adding module, the signal of which is connected to the data display module, is used to detect the drug names in the first medication history list using a weight evaluation indicator to evaluate the weights of the drug names, and sort the drug names in the first medication history list according to the weights and filter and add them to a second medication history list; a same ingredient repeated medication reminder module, the signal of which is connected to the data display module A group is used to detect the ingredient names of the drug names in the second medication history list by using a same ingredient duplication indicator to select the drug names with the same ingredients used in different hospitals and use color to prompt the repeated same ingredients for evaluation whether to renew; and a drug name click renewal or deletion module, the signal of which is connected to the data display module, and is used to click at least one of the drug names in the second medication history list to renew or delete it.
如上述之智慧化用藥處方建議系統，更包含：一減少藥物交互作用提示模組，訊號連接該資料顯示模組，用以利用一藥物交互作用指標偵測該第二藥歷清單列表之該些藥品名稱的成分名稱，以挑選出不同醫院所使用不同成分的該些藥品名稱彼此之間會產生藥物交互作用，並用顏色提示有藥物交互作用的不同成分，以供評估是否續用。The intelligent medication prescription recommendation system as mentioned above further includes: a drug interaction reduction prompt module, which is signal-connected to the data display module and is used to detect the ingredient names of the drugs in the second medication history list using a drug interaction indicator to select the drug names with different ingredients used in different hospitals that will produce drug interactions with each other, and use colors to prompt different ingredients with drug interactions for evaluation of whether to continue using them.
如上述之智慧化用藥處方建議系統，其中該權重評估指標的考量參數係選自慢性藥品、本院醫療體系藥品、非本院醫療體系藥品、雲端藥歷天數大於7天、病人年齡、藥物劑型、藥物給藥頻次、藥物副作用或過敏史、重複用藥、藥物交互作用、病人生活習慣-抽菸、病人生活習慣-喝酒、病人肝功能、病人腎功能、病人共病、懷孕和藥物、基因與藥物之一或其組合。For example, in the above-mentioned intelligent medication prescription recommendation system, the consideration parameters of the weight evaluation index are selected from chronic drugs, drugs in the hospital's medical system, drugs outside the hospital's medical system, cloud medication history greater than 7 days, patient age, drug dosage form, drug administration frequency, drug side effects or allergy history, repeated medication, drug interactions, patient lifestyle-smoking, patient lifestyle-drinking, patient liver function, patient kidney function, patient comorbidity, pregnancy and drugs, genes and drugs, or one or a combination thereof.
如上述之智慧化用藥處方建議系統，其中該藥品名稱權重偵測加入模組更包含：一權重評估指標建立模組，用以建立該權重評估指標，其中該權重評估指標建立模組包含：一權重評估指標參數設定單元，用以設定該權重評估指標所需要的複數個考量參數；以及一權重評估指標評分設定單元，訊號連接該權重評估指標參數設定單元，用以設定該些考量參數所對應的複數個評分。As mentioned above, the intelligent medication prescription recommendation system, wherein the drug name weight detection module further includes: a weight evaluation index establishment module for establishing the weight evaluation index, wherein the weight evaluation index establishment module includes: a weight evaluation index parameter setting unit for setting a plurality of consideration parameters required for the weight evaluation index; and a weight evaluation index scoring setting unit, signal-connected to the weight evaluation index parameter setting unit, for setting a plurality of scores corresponding to the consideration parameters.
如上述之智慧化用藥處方建議系統，更包含：一藥品名稱點選加入模組，訊號連接該資料顯示模組，用以點選該第一藥歷清單列表之該些藥品名稱中之至少一該藥品名稱，以加入到該第二藥歷清單列表。The intelligent medication prescription recommendation system as mentioned above further includes: a drug name click-to-add module, the signal of which is connected to the data display module, for clicking at least one of the drug names in the first medication history list to add it to the second medication history list.
本發明所提供的智慧化用藥處方建議方法具有以下優點：The intelligent medication prescription recommendation method provided by the present invention has the following advantages:
1. 本發明所提供的智慧化用藥處方建議方法，其能針對重複用藥進行提示，透過一相同成分重複指標偵測藥歷清單列表中之藥品的成分名稱，以挑選出不同醫院使用相同成分的藥品名稱，並用顏色提示有重複的相同成分，以方便供醫師評估是否續用。1. The intelligent medication prescription recommendation method provided by the present invention can provide reminders for duplicate medications. It detects the ingredient names of drugs in the medication history list through a same ingredient duplication indicator to select the names of drugs with the same ingredients used in different hospitals, and uses color to indicate the repeated same ingredients to facilitate doctors to evaluate whether to continue using them.
2. 本發明所提供的智慧化用藥處方建議方法，其能針對原始藥歷清單列表中的藥品名稱進行權重偵測排序後整合篩選成一用藥種類較少的藥歷清單列表，利用一權重評估指標偵測原始藥歷清單列表中的藥品名稱以進行權重評估，且依照權重大小進行排序並篩選加入到一新的藥歷清單列表，如此達到用藥整合的效果，以方便供醫師進行用藥選擇評估。2. The intelligent medication prescription recommendation method provided by the present invention can detect and sort the drug names in the original medication history list by weight, and then integrate and screen them into a medication history list with fewer medication types. A weight evaluation indicator is used to detect the drug names in the original medication history list to perform weight evaluation, and the drug names are sorted and screened according to the weight to be added to a new medication history list, thereby achieving the effect of medication integration to facilitate doctors to conduct medication selection evaluation.
3. 本發明所提供的智慧化用藥處方建議方法，其能針對減少藥物交互作用進行提示，利用一藥物交互作用指標偵測藥歷清單列表中之藥品的成分名稱，以挑選出不同醫院所使用不同成分的藥品彼此之間會產生藥物交互作用，並用顏色提示有藥物交互作用的不同成分，以方便供醫師評估是否續用。3. The intelligent medication prescription recommendation method provided by the present invention can provide prompts for reducing drug interactions. It uses a drug interaction indicator to detect the ingredient names of drugs in the medical history list to select drugs with different ingredients used in different hospitals that will produce drug interactions with each other, and uses colors to prompt different ingredients with drug interactions to facilitate doctors to evaluate whether to continue using them.
為達上述之目的，本發明之一實施方式在於提供一種智慧化用藥處方建議方法1，如圖1所示，其係包含以下步驟：To achieve the above-mentioned purpose, one embodiment of the present invention is to provide a smart medication prescription recommendation method 1, as shown in FIG1 , which comprises the following steps:
一藥歷資料取得步驟11，獲取一病患的藥歷資料，該藥歷資料的資料來源包含一雲端藥歷及一本院藥歷，該藥歷資料中包含有複數個藥品名稱及使用該些藥品名稱之該雲端藥歷及該本院藥歷；一藥品名稱排序步驟12，智慧排序該些藥品名稱，以將該些藥品名稱按照英文字母順序進行排序，匯入並顯示於一第一藥歷清單列表；一資料來源提示步驟13，利用顏色標示該藥歷資料的資料來源，以將該藥歷資料的資料來源中的該雲端藥歷及該本院藥歷分別以不同顏色顯示於該第一藥歷清單列表；一藥品名稱權重偵測步驟14，利用一權重評估指標偵測該第一藥歷清單列表之該些藥品名稱，以對該些藥品名稱進行權重評估；一藥品名稱權重排序加入步驟15，將該第一藥歷清單列表中的該些藥品名稱依照權重大小進行排序並篩選加入到一第二藥歷清單列表；一藥品名稱點選加入步驟16，點選該第一藥歷清單列表之該些藥品名稱中之至少一該藥品名稱，以加入到一第二藥歷清單列表；一相同成分重複用藥提示步驟17，利用一相同成分重複指標偵測該第二藥歷清單列表之該些藥品名稱的成分名稱，以挑選出不同醫院使用相同成分的該些藥品名稱，並用顏色提示有重複的相同成分，以供評估是否續用；一減少藥物交互作用提示步驟18，利用一藥物交互作用指標偵測該第二藥歷清單列表之該些藥品名稱的成分名稱，以挑選出不同醫院所使用不同成分的該些藥品名稱彼此之間會產生藥物交互作用，並用顏色提示有藥物交互作用的不同成分，以供評估是否續用；及一藥品名稱點選續用或刪除步驟19，點選該第二藥歷清單列表之該些藥品名稱中之至少一該藥品名稱並予以續用或刪除。A drug history data acquisition step 11, obtaining drug history data of a patient, the data source of the drug history data includes a cloud drug history and a hospital drug history, the drug history data includes a plurality of drug names and the cloud drug history and the hospital drug history using the drug names; a drug name sorting step 12, intelligently sorting the drug names, so as to sort the drug names in alphabetical order, import and display them in a first drug history list; a data source prompting step 13, using color to mark the drug The data source of the medical history data is determined, so that the cloud medical history and the hospital medical history in the data source of the medical history data are displayed in different colors in the first medical history list; a drug name weight detection step 14, using a weight evaluation index to detect the drug names in the first medical history list to evaluate the weights of the drug names; a drug name weight sorting step 15, sorting the drug names in the first medical history list according to the weights and screening them to be added to a second medical history list. a drug name selection step 16, in which at least one of the drug names in the first drug history list is selected to be added to a second drug history list; a same-ingredient duplicate medication prompt step 17, in which the names of the drug names in the second drug history list are detected using a same-ingredient duplicate indicator to select the drug names with the same ingredients used in different hospitals, and use color to prompt the duplicated same ingredients for evaluation of whether to continue using; a drug reduction step 17, in which the same-ingredient duplicate indicator is used to detect the ingredient names of the drug names in the second drug history list to select the same-ingredient drug names used in different hospitals, and use color to prompt the repeated same ingredients for evaluation of whether to continue using; An interaction prompting step 18, using a drug interaction indicator to detect the ingredient names of the drug names in the second medication history list, to select the drug names of different ingredients used in different hospitals that will produce drug interactions with each other, and use colors to prompt the different ingredients with drug interactions for evaluation of whether to continue using; and a drug name selection to continue or delete step 19, clicking at least one of the drug names in the second medication history list to renew or delete it.
值得一提的是，這裡的本院藥歷指的是病患親自去就醫的那一家醫院所記錄下來的藥歷，而所謂的雲端藥歷指的是病患之前在其他家醫院就診時所記錄留下的藥歷，可理解的是，若本院藥歷中的那一家醫院若為包含有分院的連鎖醫療體系，則本院藥歷除了有在本院的病患藥歷外，同時還包含病患在分院的藥歷。例如像是義大醫療體系，則本院藥歷除了義大醫院以外，還會包含義大癌治療醫院及義大大昌醫院。因此，若病患去義大醫院親自就醫，則本院藥歷的資料來源同時包含義大醫院、義大癌治療醫院及義大大昌醫院，而不屬於義大醫療體系的其他醫院則被界定為雲端藥歷。It is worth mentioning that the main hospital medical records here refer to the medical records recorded by the hospital where the patient went to see the doctor in person, and the so-called cloud medical records refer to the medical records recorded by the patient when he or she was previously treated in other hospitals. It can be understood that if the hospital in the main hospital medical records is a chain medical system that includes branches, then the main hospital medical records include not only the medical records of patients in the main hospital, but also the medical records of patients in the branches. For example, in the E-Da Medical System, the main hospital medical records include E-Da Cancer Treatment Hospital and E-Da Chang Hospital in addition to E-Da Hospital. Therefore, if the patient goes to E-Da Hospital for medical treatment in person, the data source of the main hospital medical records includes E-Da Hospital, E-Da Cancer Treatment Hospital and E-Da Chang Hospital at the same time, and other hospitals that are not part of the E-Da Medical System are defined as cloud medical records.
在本實施例中，例如病患去義大醫院親自就醫，醫療人員經由藥歷資料取得步驟11，可獲取該病患的藥歷資料，該藥歷資料的資料來源包含一雲端藥歷及一本院藥歷，且該藥歷資料中包含有分別在雲端藥歷及本院藥歷中所使用的複數個藥品名稱。接著。透過藥品名稱排序步驟12，智慧排序該些藥品名稱，以將該些藥品名稱按照英文字母順序進行排序，匯入並顯示於一第一藥歷清單列表，如圖2所示。之後，經由資料來源提示步驟13，利用顏色標示該藥歷資料的資料來源，以將該藥歷資料的資料來源中的該雲端藥歷及該本院藥歷分別以不同顏色顯示於該第一藥歷清單列表。In this embodiment, for example, when a patient goes to E-Da Hospital for medical treatment in person, the medical staff can obtain the patient's medical history data through the medical history data acquisition step 11. The data source of the medical history data includes a cloud medical history and a medical history of the hospital, and the medical history data includes a plurality of drug names used in the cloud medical history and the medical history of the hospital. Then, through the drug name sorting step 12, the drug names are intelligently sorted so that the drug names are sorted in alphabetical order, imported and displayed in a first medical history list, as shown in FIG2. Afterwards, through the data source prompting step 13, the data source of the medication record data is marked with color, so that the cloud medication record and the in-hospital medication record in the data source of the medication record data are displayed in the first medication record list in different colors.
再者，經由藥品名稱權重偵測步驟14及藥品名稱權重排序加入步驟15，利用一權重評估指標偵測該第一藥歷清單列表之該些藥品名稱，以對該些藥品名稱進行權重評估，且將該第一藥歷清單列表中的該些藥品名稱依照權重大小進行排序並篩選加入到一第二藥歷清單列表，如圖3所示。可理解的是，醫療人員可設定權重篩選標準，以使權重大於一設定標準值或評估分數的藥品名稱才可順利加入到該第二藥歷清單列表，權重不符合此設定標準值或評估分數的藥品名稱則不加入到該第二藥歷清單列表，如此以達到整合不同醫院之間所使用不同用藥種類的目的，藉此能夠有效減少用藥的種類。Furthermore, through the drug name weight detection step 14 and the drug name weight sorting step 15, a weight evaluation indicator is used to detect the drug names in the first drug history list to perform weight evaluation on the drug names, and the drug names in the first drug history list are sorted according to the weight and screened to be added to a second drug history list, as shown in Figure 3. It is understandable that medical personnel can set weight screening criteria so that only drug names with weights greater than a set standard value or evaluation score can be successfully added to the second medication history list, and drug names whose weights do not meet the set standard value or evaluation score will not be added to the second medication history list. In this way, the purpose of integrating different types of medications used in different hospitals can be achieved, thereby effectively reducing the types of medications used.
以本實施例而言，請參考圖2及圖3，可發現整合前的第一藥歷清單列表中有8種藥，而整合後的第二藥歷清單列表中只有5種藥，故可以有效減少用藥種類，以提供給醫療人員智慧化的用藥建議。此外，第一藥歷清單列表及第二藥歷清單列表係同時呈現在同一頁面，因此來源資料也同時呈現在同一用藥智慧化建議頁面中，所以可方便醫療人員一目了然的參酌使用。可理解的是，在圖2及圖3中之第一藥歷清單列表與第二藥歷清單列表中呈現於用藥智慧化建議頁面中的欄位名稱只是一種範例，在一些其他實施例中，如圖4所示，可以有其他不同欄位名稱的設計，亦即本發明可針對實際醫療人員需求作各種不同欄位設計以作為權重偵測評分之用。In this embodiment, please refer to Figures 2 and 3. It can be found that there are 8 drugs in the first medication history list before integration, and there are only 5 drugs in the second medication history list after integration, so the types of medications can be effectively reduced to provide medical personnel with intelligent medication recommendations. In addition, the first medication history list and the second medication history list are presented on the same page at the same time, so the source data is also presented on the same intelligent medication recommendation page at the same time, so it is convenient for medical personnel to refer to and use at a glance. It is understandable that the field names presented in the first medication history list and the second medication history list in Figures 2 and 3 on the intelligent medication recommendation page are just examples. In some other embodiments, as shown in Figure 4, there may be other different field name designs, that is, the present invention can be designed with various different fields for the purpose of weight detection and scoring according to the actual needs of medical personnel.
此外，除了透過上述之藥品名稱權重偵測步驟14及藥品名稱權重排序加入步驟15外，還可另外透過一藥品名稱點選加入步驟16，經由醫療人員直接點選該第一藥歷清單列表之該些藥品名稱中之至少一該藥品名稱，以點選加入到一第二藥歷清單列表。可理解的是，此藥品名稱點選加入步驟16係為選擇性的，並非是強制醫療人員必須一定要去點選第一藥歷清單列表之該些藥品名稱中之至少一該藥品名稱去加入到第二藥歷清單列表。In addition, in addition to the above-mentioned drug name weight detection step 14 and drug name weight sorting step 15, a drug name click-to-add step 16 can also be performed, whereby the medical staff can directly click at least one of the drug names in the first drug history list to add the drug to a second drug history list. It is understandable that the drug name click-to-add step 16 is optional and does not force the medical staff to click at least one of the drug names in the first drug history list to add the drug to the second drug history list.
再者，透過相同成分重複用藥提示步驟17，利用一相同成分重複指標偵測該第二藥歷清單列表之該些藥品名稱的成分名稱，以挑選出不同醫院使用相同成分的該些藥品名稱，並利用顏色提示有重複的相同成分，以供醫療人員評估是否要續用此藥品，其中重複用藥提示是依據雲端藥歷、不同醫院、相同ATC Code前五碼，需以顏色區分並聚集。此時，若是要續用或是不續用此藥品，可透過一藥品名稱點選續用或刪除步驟19，一鍵點選該第二藥歷清單列表之該些藥品名稱中之有重複的相同成分的藥品名稱並予以續用或刪除。因此，透過此相同成分重複用藥提示步驟17，就可有效減少重複用藥的藥品浪費，以減少藥品使用的成本。Furthermore, through the same ingredient duplicate medication prompt step 17, a same ingredient duplicate indicator is used to detect the ingredient names of the drug names in the second medication history list, to select the drug names of the same ingredients used in different hospitals, and use color to prompt the duplicated same ingredients for medical personnel to evaluate whether to continue using the drug. The duplicate medication prompt is based on the cloud medication history, different hospitals, and the first five digits of the same ATC Code, and needs to be distinguished and clustered by color. At this time, if you want to continue or not continue using the drug, you can click on the drug name to continue or delete the drug name in the second medication history list with one click in step 19, and continue or delete it. Therefore, through the same component repeated medication prompt step 17, the waste of repeated medication can be effectively reduced, thereby reducing the cost of medication use.
此外，還可另外透過一減少藥物交互作用提示步驟18，利用一藥物交互作用指標偵測該第二藥歷清單列表之該些藥品名稱的成分名稱，以挑選出不同醫院所使用不同成分的該些藥品名稱彼此之間會產生藥物交互作用，並用顏色提示有藥物交互作用的不同成分，以供醫療人員評估是否要續用此藥品。同樣的，在此時若是要續用或是不續用此藥品，可透過一藥品名稱點選續用或刪除步驟19，一鍵點選該第二藥歷清單列表之該些藥品名稱中之有重複的相同成分的藥品名稱並予以續用或刪除。因此，透過此減少藥物交互作用提示步驟18，就可有效減少藥物交互作用所產生用藥失效的藥品浪費，以減少藥品使用的成本。In addition, a drug interaction reduction prompt step 18 can be used to detect the names of the ingredients of the drug names in the second medication history list using a drug interaction indicator to select the drug names of different ingredients used in different hospitals that will cause drug interactions, and use colors to prompt the different ingredients with drug interactions, so that medical personnel can evaluate whether to continue using the drug. Similarly, if you want to continue or not continue using the drug at this time, you can click on the drug name to continue or delete the drug names with the same ingredients in the drug names in the second medication history list and continue or delete them. Therefore, through the step 18 of reducing drug interactions, the waste of drugs due to ineffective drug use caused by drug interactions can be effectively reduced, thereby reducing the cost of drug use.
在本實施例中，該藥品名稱權重偵測步驟14中之該權重評估指標的考量參數包含慢性病藥品、該本院藥歷中已使用藥品、該雲端藥歷中已使用的藥品及該雲端藥歷中有使用超過7天的藥品。然不在此限，也可依照醫療人員的需求加入其他評估條件做為考量參數。可理解的是，例如可將藥歷中使用超過7天的限制條件修改成為其他天數如10天、14天、21天或是30天。而此限制天數除了可應用於雲端藥歷中，也可應用於本院藥歷中。In this embodiment, the consideration parameters of the weight evaluation index in the drug name weight detection step 14 include chronic disease drugs, drugs used in the hospital's medical records, drugs used in the cloud medical records, and drugs used for more than 7 days in the cloud medical records. However, this is not limited to other evaluation conditions and can be added as consideration parameters according to the needs of medical personnel. It is understandable that, for example, the restriction condition of using more than 7 days in the medical record can be modified to other days such as 10 days, 14 days, 21 days or 30 days. In addition to being applied to the cloud medical record, this restriction can also be applied to the hospital's medical record.
在一些實施例中，如圖5所示，該藥品名稱權重偵測步驟14中包含：一權重評估指標建立步驟141，建立該權重評估指標，其中該權重評估指標建立步驟141包含一權重評估指標參數設定步驟142，設定該權重評估指標所需要的複數個考量參數或項目；以及一權重評估指標評分設定步驟143，設定該些考量參數或項目所對應的複數個評分或分數。在一些實施例中，例如權重評估指標中的內容設計，該些考量參數或項目的設定為慢性病藥品、義大醫療體系藥品、非義大醫療體系藥品及雲端藥歷天數，而將該些考量參數設定其所對應的複數個評分，例如慢性病藥品是5分，義大醫療體系藥品是4分，非義大醫療體系藥品是3分，雲端藥歷天數大於7天是4分等等。In some embodiments, as shown in FIG. 5 , the drug name weight detection step 14 includes: a weight evaluation index establishment step 141, establishing the weight evaluation index, wherein the weight evaluation index establishment step 141 includes a weight evaluation index parameter setting step 142, setting a plurality of consideration parameters or items required for the weight evaluation index; and a weight evaluation index score setting step 143, setting a plurality of scores or points corresponding to the consideration parameters or items. In some embodiments, such as the content design in the weight evaluation index, the consideration parameters or items are set as chronic disease drugs, E-Da medical system drugs, non-E-Da medical system drugs and cloud medication days, and the consideration parameters are set to their corresponding multiple scores, for example, chronic disease drugs are 5 points, E-Da medical system drugs are 4 points, non-E-Da medical system drugs are 3 points, cloud medication days greater than 7 days are 4 points, and so on.
值得一提的是，這裡所考量的參數或項目的評分設定的依據係來自於本院資深醫師所累積的對病患用藥經驗值所得出的統計結果，亦即透過資深醫師的用藥經驗值來做為輔助設定權重評估指標之參數或項目的評分，將有助於年輕醫師在用藥選擇上的參考及判斷。然不限於此，此參數或項目的評分設定的依據也可參考來自於健保署的相關醫療大數據統計分析結果，或是參考來自於經過AI 醫療用藥數據分析的結果，亦即本發明對於權重參數或項目的評分設定係有一定科學的依據，並利用此一定科學的依據去評分各個權重參數或項目。It is worth mentioning that the basis for the scoring of the parameters or items considered here is the statistical results of the accumulated experience of the senior doctors in the hospital with patients. That is, the use of the senior doctors' experience in medication as an auxiliary to set the parameters or items of the weight evaluation index will help young doctors to refer to and judge the choice of medication. However, it is not limited to this. The basis for the scoring of this parameter or item can also refer to the statistical analysis results of relevant medical big data from the National Health Insurance Administration, or refer to the results of AI medical medication data analysis. That is, the present invention has a certain scientific basis for the scoring of weight parameters or items, and uses this certain scientific basis to score each weight parameter or item.
因此，本發明特別將需要設定為權重考量的參數或項目，依照實際資深醫師所累積的經驗界定為包含以下項目：慢性藥品、本院醫療體系藥品、非本院醫療體系藥品、雲端藥歷天數大於7天、病人年齡、藥物劑型、藥物給藥頻次、藥物副作用或過敏史、重複用藥、藥物交互作用、病人生活習慣-抽菸、病人生活習慣-喝酒、病人肝功能、病人腎功能、病人共病、懷孕和藥物、基因與藥物等17項，並將此17項需要考量的權重項目及其理由說明與分數整理成如下表1所示。可以理解的是，然不限於此，也可因為後續實際需求增減表1中的項目或參數，例如像是由於COVID-19等的流行病產生時，注射疫苗是否會對用藥產生影響也可列入此權重所要考量的參數或項目中。 表1 權重項目及其說明與分數
因此，在一些實施例中，如圖5所示，該權重評估指標建立步驟141更包含一權重評估指標參數更新設定步驟144，設定該權重評估指標所需要增減更新的至少一個考量參數或項目；以及一權重評估指標評分更新設定步驟145，設定該增減更新的至少一個考量參數或項目所對應的至少一個評分或分數。可以理解的是，也可以省略該權重評估指標參數更新設定步驟144，而直接進行權重評估指標評分更新設定步驟145，此即表示在未改變原有的考量參數或項目的情況之下，只針對原有的參數或項目的評分或分數進行修改調整。Therefore, in some embodiments, as shown in FIG5 , the weight evaluation index establishment step 141 further includes a weight evaluation index parameter update setting step 144, which sets at least one consideration parameter or item that needs to be increased or decreased for the weight evaluation index; and a weight evaluation index score update setting step 145, which sets at least one score or number corresponding to the at least one consideration parameter or item that needs to be increased or decreased for the update. It is understandable that the weight evaluation index parameter update setting step 144 can also be omitted, and the weight evaluation index score update setting step 145 can be directly performed, which means that without changing the original consideration parameters or items, only the scores or numbers of the original parameters or items are modified and adjusted.
本發明之另一實施方式在於提供一種智慧化用藥處方建議系統2，如圖6所示，其包含：一資料接收模組21，用以獲取一病患的藥歷資料，該藥歷資料的資料來源包含一雲端藥歷及一本院藥歷，該藥歷資料中包含有複數個藥品名稱及使用該些藥品名稱之該雲端藥歷及該本院藥歷；一資料顯示模組22，訊號連接該資料接收模組21，用以顯示出該病患的藥歷資料；一智慧排序模組23，訊號連接該資料顯示模組22，用以智慧排序該病患的藥歷資料中所出現的該些藥品名稱，以將該些藥品名稱按照英文字母順序進行排序，匯入並顯示於一第一藥歷清單列表；一資料來源提示模組24，訊號連接該資料顯示模組22，用以利用顏色標示該藥歷資料的資料來源，以將該藥歷資料的資料來源中的該雲端藥歷及該本院藥歷分別以不同顏色顯示於該第一藥歷清單列表；一藥品名稱權重偵測加入模組25，訊號連接該資料顯示模組22，用以利用一權重評估指標偵測該第一藥歷清單列表之該些藥品名稱，以對該些藥品名稱進行權重評估，且將該第一藥歷清單列表中的該些藥品名稱依照權重大小進行排序並篩選加入到一第二藥歷清單列表；及一相同成分重複用藥提示模組26，訊號連接該資料顯示模組22，用以利用一相同成分重複指標偵測該第二藥歷清單列表之該些藥品名稱的成分名稱，以挑選出不同醫院使用相同成分的該些藥品名稱，並用顏色提示有重複的相同成分，以供評估是否續用。Another embodiment of the present invention is to provide an intelligent medication prescription recommendation system 2, as shown in FIG6, which includes: a data receiving module 21, used to obtain a patient's medication history data, the data source of the medication history data includes a cloud medication history and a hospital medication history, the medication history data includes a plurality of drug names and the cloud medication history and the hospital medication history using the drug names; a data display module 22, signal connected to the data receiving module 21 Module 21, for displaying the patient's medication history data; a smart sorting module 23, signal-connected to the data display module 22, for smartly sorting the drug names appearing in the patient's medication history data, so as to sort the drug names in alphabetical order, import and display them in a first medication history list; a data source prompting module 24, signal-connected to the data display module 22, for marking the medication history with colors The data source of the drug history data is to display the cloud drug history and the hospital drug history in the data source of the drug history data in different colors in the first drug history list; a drug name weight detection module 25 is added, and the signal is connected to the data display module 22 to detect the drug names in the first drug history list using a weight evaluation indicator to evaluate the weights of the drug names and add the drug names in the first drug history list to the drug history list. The drug names are sorted according to their weights and screened to be added to a second medication history list; and a same-ingredient duplicate medication reminder module 26, which is signal-connected to the data display module 22, is used to detect the ingredient names of the drug names in the second medication history list using a same-ingredient duplicate indicator to select the drug names with the same ingredients used in different hospitals, and use color to prompt the repeated same ingredients for evaluation of whether to continue using them.
此外，還可另外設置一藥品名稱點選加入模組27，訊號連接該資料顯示模組22，用以供醫療人員自由點選該第一藥歷清單列表之該些藥品名稱中之至少一該藥品名稱，以加入到一第二藥歷清單列表。可理解的是，前述有提到藥品名稱點選加入步驟16係為選擇性的，因此，該藥品名稱點選加入模組27也是可選擇性的設置，並非是必要模組。再者，還可設置一減少藥物交互作用提示模組28，訊號連接該資料顯示模組22，用以利用一藥物交互作用指標偵測該第二藥歷清單列表之該些藥品名稱的成分名稱，以挑選出不同醫院所使用不同成分的該些藥品名稱彼此之間會產生藥物交互作用，並用顏色提示有藥物交互作用的不同成分，以供評估是否續用。In addition, a drug name click-to-add module 27 may be provided, which is signal-connected to the data display module 22, so that medical personnel can freely click on at least one of the drug names in the first medication history list to add it to a second medication history list. It is understandable that the aforementioned drug name click-to-add step 16 is optional, and therefore, the drug name click-to-add module 27 is also an optional setting and is not a necessary module. Furthermore, a drug interaction reduction prompt module 28 may be provided, which is signal-connected to the data display module 22, and is used to detect the ingredient names of the drugs in the second medication history list using a drug interaction indicator, so as to select the drug names of different ingredients used in different hospitals that may cause drug interactions with each other, and use colors to prompt the different ingredients with drug interactions for evaluation of whether to continue using them.
再者，針對前面提及的使用相同成分重複用藥提示模組26及藥物交互作用提示模組28所挑選出來有爭議需評估的藥品，可透過一藥品名稱點選續用或刪除模組29，其訊號連接該資料顯示模組22，用以點選該第二藥歷清單列表之該些藥品名稱中之此些有爭議需要評估的藥品，予以續用或刪除。Furthermore, for the controversial drugs that need to be evaluated selected by the aforementioned repeated use of the same ingredient reminder module 26 and the drug interaction reminder module 28, a drug name click renewal or deletion module 29 can be used, and its signal is connected to the data display module 22, so as to click on these controversial drugs that need to be evaluated in the drug names in the second medication history list to renew or delete them.
此外，在本實施例中，該權重評估指標的考量參數包含慢性病藥品、該本院藥歷中已使用藥品、該雲端藥歷中已使用的藥品及該雲端藥歷中有使用超過7天的藥品。此外，在一些實施例中，此7天的藥品亦可隨著實際需求修改成10天、14天、21天或30天。In addition, in this embodiment, the parameters considered in the weight evaluation index include chronic disease drugs, drugs used in the hospital's medical history, drugs used in the cloud medical history, and drugs used for more than 7 days in the cloud medical history. In addition, in some embodiments, the 7-day drug can also be modified to 10 days, 14 days, 21 days or 30 days according to actual needs.
再者，該藥品名稱權重偵測加入模組25更包含：一權重評估指標建立模組251，用以建立該權重評估指標，其中該權重評估指標建立模組251包含一權重評估指標參數設定單元252，用以設定該權重評估指標所需要的複數個考量參數；以及一權重評估指標評分設定單元253，訊號連接該權重評估指標參數設定單元252，用以設定該些考量參數所對應的複數個評分。此外，在一些實施例中，如圖7所示，該權重評估指標建立模組251更包含一權重評估指標參數更新設定單元254，用以設定該權重評估指標所需要增減更新的至少一個考量參數或項目；以及一權重評估指標評分更新設定單元255，訊號連接該權重評估指標參數更新設定單元254，用以設定該增減更新的至少一個考量參數或項目所對應的至少一個評分或分數。Furthermore, the drug name weight detection module 25 further includes: a weight evaluation index establishment module 251 for establishing the weight evaluation index, wherein the weight evaluation index establishment module 251 includes a weight evaluation index parameter setting unit 252 for setting a plurality of consideration parameters required for the weight evaluation index; and a weight evaluation index scoring setting unit 253, which is signal-connected to the weight evaluation index parameter setting unit 252 for setting a plurality of scores corresponding to the consideration parameters. In addition, in some embodiments, as shown in Figure 7, the weight evaluation indicator establishment module 251 further includes a weight evaluation indicator parameter update setting unit 254, which is used to set at least one consideration parameter or item that needs to be increased or decreased and updated for the weight evaluation indicator; and a weight evaluation indicator score update setting unit 255, which is signal-connected to the weight evaluation indicator parameter update setting unit 254, and is used to set at least one score or number corresponding to the at least one consideration parameter or item that needs to be increased or decreased and updated.
綜上所述，本發明所提供的智慧化用藥處方建議方法，其能針對重複用藥進行提示、針對藥物交互作用進行提示以及針對藥品名稱進行權重偵測排序整合建議，因此能夠大幅減少重複用藥的藥品浪費、藥物交互作用的用藥失效及使用藥品的種類數量，故能有效減少藥品使用的成本及負擔，並可減輕醫療人員針對病患用藥的處理時間及精力。此外，本發明所提供的智慧化用藥處方建議方法所呈現的用藥智慧化建議頁面，其具有五大獨創功能，包含來源一頁面、續用一鍵點、智慧給排序、權重給建議及顏色防開錯，所以能讓醫療人員在給病患用藥開處方時，可透過此用藥智慧化建議頁面，對病患的藥歷一目了然，以方便快速達到精準用藥、減少藥品使用的浪費、降低藥品使用的成本與負擔及減輕醫療人員針對病患用藥的處理時間與精力。In summary, the intelligent medication prescription recommendation method provided by the present invention can provide reminders for duplicate medication, reminders for drug interactions, and weight detection, sorting, and integrated recommendations for drug names, thereby significantly reducing drug waste due to duplicate medication, drug ineffectiveness due to drug interactions, and the number of types of drugs used, thereby effectively reducing the cost and burden of drug use, and reducing the time and energy of medical personnel in handling patient medication. In addition, the intelligent medication prescription recommendation method provided by the present invention presents an intelligent medication recommendation page, which has five original functions, including one page for source, one-click for renewal, intelligent sorting, weighted recommendations, and color-coded error prevention. Therefore, when prescribing medication for patients, medical personnel can use this intelligent medication recommendation page to have a clear view of the patient's medication history, so as to facilitate and quickly achieve accurate medication, reduce waste of drug use, reduce the cost and burden of drug use, and reduce the time and energy of medical personnel in handling patient medication.
當理解的是，前述對實施方式的描述僅是以實施例的方式給出，且本領域所屬技術領域中具有通常知識者都可進行各種修改。以上說明書及實施例提供本發明之例示性實施方式之流程與其用途的完整描述。雖然上文實施方式中揭露了本發明的具體實施例，然其並非用以限定本發明，本發明所屬技術領域中具有通常知識者，在不悖離本發明之原理與精神的情形下，當可對其進行各種更動與修飾，因此本發明之保護範圍當以附隨申請專利範圍所界定者為準。It should be understood that the above description of the embodiments is given only in the form of embodiments, and various modifications can be made by those with ordinary knowledge in the art to which this invention belongs. The above specification and embodiments provide a complete description of the process and use of the exemplary embodiments of the present invention. Although the above embodiments disclose specific embodiments of the present invention, they are not used to limit the present invention. Those with ordinary knowledge in the art to which the present invention belongs can make various changes and modifications without departing from the principles and spirit of the present invention. Therefore, the scope of protection of the present invention shall be based on the scope defined by the attached patent application.
1:智慧化用藥處方建議方法 11:藥歷資料取得步驟 12:藥品名稱排序步驟 13:資料來源提示步驟 14:藥品名稱權重偵測步驟 141:權重評估指標建立步驟 142:權重評估指標參數設定步驟 143:權重評估指標評分設定步驟 144:權重評估指標參數更新設定步驟 145:權重評估指標評分更新設定步驟 15:藥品名稱權重排序加入步驟 16:藥品名稱點選加入步驟 17:相同成分重複用藥提示步驟 18:減少藥物交互作用提示步驟 19:藥品名稱點選續用或刪除步驟 2:智慧化用藥處方建議系統 21:資料接收模組 22:資料顯示模組 23:智慧排序模組 24:資料來源提示模組 25:藥品名稱權重偵測加入模組 251:權重評估指標建立模組 252:權重評估指標參數設定單元 253:權重評估指標評分設定單元 254:權重評估指標參數更新設定單元 255:權重評估指標評分更新設定單元 26:相同成分重複用藥提示模組 27:藥品名稱點選加入模組 28:減少藥物交互作用提示模組 29:藥品名稱點選續用或刪除模組1: Intelligent medication prescription recommendation method11: Medical history data acquisition step12: Drug name sorting step13: Data source prompt step14: Drug name weight detection step141: Weight evaluation index establishment step142: Weight evaluation index parameter setting step143: Weight evaluation index score setting step144: Weight evaluation index parameter update setting step145: Weight evaluation index score update setting step15: Drug name weight sorting adding step16: Drug name click adding step17: Same ingredient duplicate medication prompt step18: Reduce drug interaction prompt step19: Click on the drug name to continue or delete the step2: Intelligent medication prescription recommendation system21: Data receiving module22: Data display module23: Intelligent sorting module24: Data source prompt module25: Drug name weight detection module251: Weight evaluation index establishment module252: Weight evaluation index parameter setting unit253: Weight evaluation index scoring setting unit254: Weight evaluation index parameter update setting unit255: Weight evaluation index scoring update setting unit26: Same ingredient duplicate medication prompt module27: Drug name click to add module28: Reduce drug interaction prompt module29: Click on the drug name to continue or delete the module
圖1係本發明之一種智慧化用藥處方建議方法的流程方塊圖。 圖2係本發明之藥歷資料透過藥品名稱排序匯入並顯示於第一藥歷清單列表之外觀示意圖。 圖3係本發明之藥品名稱經由權重偵測排序加入於第二藥歷清單列表之外觀示意圖。 圖4係本發明之藥歷清單列表中的不同欄位名稱的另一設計範例之示意圖。 圖5係本發明之一種權重評估指標建立步驟的流程方塊圖。 圖6係本發明之一種智慧化用藥處方建議系統的結構方塊圖。 圖7係本發明之一種權重評估指標建立模組的結構方塊圖。FIG. 1 is a flow block diagram of a smart medication prescription recommendation method of the present invention.FIG. 2 is an external schematic diagram of the medication history data of the present invention being imported by sorting the drug names and displayed in the first medication history list.FIG. 3 is an external schematic diagram of the drug names of the present invention being added to the second medication history list by weight detection sorting.FIG. 4 is a schematic diagram of another design example of different field names in the medication history list of the present invention.FIG. 5 is a flow block diagram of a weight evaluation index establishment step of the present invention.FIG. 6 is a structural block diagram of a smart medication prescription recommendation system of the present invention.FIG. 7 is a structural block diagram of a weight evaluation index establishment module of the present invention.
1:智慧化用藥處方建議方法1: Intelligent medication prescription recommendation method
11:藥歷資料取得步驟11: Steps to obtain medical history data
12:藥品名稱排序步驟12: Drug name sorting steps
13:資料來源提示步驟13: Data source prompt step
14:藥品名稱權重偵測步驟14: Drug name weight detection steps
15:藥品名稱權重排序加入步驟15: Add a step to re-rank drug names
16:藥品名稱點選加入步驟16: Click on the drug name to add the step
17:相同成分重複用藥提示步驟17: Tips for repeated use of the same ingredient
18:減少藥物交互作用提示步驟18: Tips for reducing drug interactions
19:藥品名稱點選續用或刪除步驟19: Click on the drug name to continue or delete the steps
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW112139377ATWI867800B (en) | 2023-10-16 | 2023-10-16 | Intelligent drug use prescription suggestion method and system |
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW112139377ATWI867800B (en) | 2023-10-16 | 2023-10-16 | Intelligent drug use prescription suggestion method and system |
| Publication Number | Publication Date |
|---|---|
| TWI867800Btrue TWI867800B (en) | 2024-12-21 |
| TW202518470A TW202518470A (en) | 2025-05-01 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW112139377ATWI867800B (en) | 2023-10-16 | 2023-10-16 | Intelligent drug use prescription suggestion method and system |
| Country | Link |
|---|---|
| TW (1) | TWI867800B (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI526977B (en)* | 2014-10-27 | 2016-03-21 | Ya-Yun Qiu | Cloud Pharmacy Care Service Platform and Method |
| CN114334077A (en)* | 2021-12-30 | 2022-04-12 | 易联众曦康(上海)智能科技有限公司 | A drug management system |
| EP4120151A1 (en)* | 2016-09-09 | 2023-01-18 | Dexcom, Inc. | Method for enabling health care provider set up of a bolus calculator |
| TWI801233B (en)* | 2022-05-04 | 2023-05-01 | 員榮醫療社團法人員榮醫院 | Remote consultation medication system |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI526977B (en)* | 2014-10-27 | 2016-03-21 | Ya-Yun Qiu | Cloud Pharmacy Care Service Platform and Method |
| EP4120151A1 (en)* | 2016-09-09 | 2023-01-18 | Dexcom, Inc. | Method for enabling health care provider set up of a bolus calculator |
| CN114334077A (en)* | 2021-12-30 | 2022-04-12 | 易联众曦康(上海)智能科技有限公司 | A drug management system |
| TWI801233B (en)* | 2022-05-04 | 2023-05-01 | 員榮醫療社團法人員榮醫院 | Remote consultation medication system |
| Publication number | Publication date |
|---|---|
| TW202518470A (en) | 2025-05-01 |
| Publication | Publication Date | Title |
|---|---|---|
| Holzemer et al. | The revised sign and symptom check-list for HIV (SSC-HIVrev) | |
| Brown et al. | Emergency department analgesia for fracture pain | |
| Bohren et al. | Continuous support for women during childbirth | |
| Shields et al. | Use of maternal early warning trigger tool reduces maternal morbidity | |
| US8032394B1 (en) | System and method for a patient-specific and optimization of medical therapy by simultaneous symbolic reasoning in all clinical dimensions | |
| Lenaerts et al. | Continuing care for patients with alcohol use disorders: a systematic review | |
| Dhall et al. | Use of potentially inappropriate drugs in nursing homes | |
| Apter et al. | Represcription of penicillin after allergic-like events | |
| Li et al. | Chinese herbal medicines for threatened miscarriage | |
| Chen et al. | Ability of machine-learning based clinical decision support system to reduce alert fatigue, wrong-drug errors, and alert users about look alike, sound alike medication | |
| Longstreth et al. | Group psychotherapy for women molested in childhood: Psychological and somatic symptoms and medical visits | |
| Roccella | Potential for reducing health care costs by public and patient education. Summary of selected studies | |
| White | Infections and infection risks in home care settings | |
| Heinemann et al. | Partners in patient care: measuring the effects on patient satisfaction and other quality indicators. | |
| TWI867800B (en) | Intelligent drug use prescription suggestion method and system | |
| De Jorna et al. | Changes in pediatric emergency department visits during a COVID-19 lockdown period: an exhaustive single-center analysis | |
| Ramanuj | Improving blood and ECG monitoring among patients prescribed regular antipsychotic medications | |
| Sabbaghi et al. | Job satisfaction among ophthalmologists in Iran | |
| Elliott et al. | Interventions for the discharge of older people to their home from the emergency department: a systematic review | |
| Strunk | Summary of workshop discussion | |
| Tawa et al. | Risk factors for chronic non communicable diseases in Mombasa, Kenya: Epidemiological study using WHO stepwise approach | |
| Townes et al. | Alcohol screening practices of primary care physicians in eastern North Carolina | |
| Solikhah et al. | How do HIV-positive elderly get infected by COVID-19 during the COVID-19 pandemic? A literature review | |
| Alkhatib et al. | Assessment of drug prescribing in Jordan using World Health Organization indicators | |
| Ayres et al. | A high incidence of asthma and respiratory symptoms in 4–11 year old children |